Treos Bio, Ltd., a London, UK- and Bethesda, MD-based developer of precision cancer immunotherapies paired to companion diagnostics, completed an $8m funding.
The investors were not disclosed.
The company intends to use the funds for the early-stage human clinical trial of its PolyPEPI™ Immunotherapy Cancer Vaccine for colorectal cancer.
Led by Dr. Menghis Bairu, Executive Chairman, and Dr. Julianna Lisziewicz, Chief Scientific Officer and co-founder, Treos has completed preclinical development of therapeutic vaccines for melanoma, lung cancer, breast cancer, glioblastoma, colorectal cancer and leukemia.
Using its companion diagnostics, the company plans to treat cancer patients who are identified as likely responders. Based on discussions with the U.S. Food and Drug Administration, Treos Bio expects to begin a first-in-man trial in 2017.